Kwa Chong Seng
Non-Independent Non-Executive Chairman
Board at 28 February 2026; appointed11November2025. Board Chairman, not Group CEO. As reported at 2026-02-28The business, the people and the ownership behind ULTRAGREEN AI USD.
Business overview
UltraGreen.ai develops fluorescence-guided surgery and imaging solutions. Its products include indocyanine green imaging agents marketed as IC-GREEN and Verdye, alongside development of imaging systems and related technologies.
Listed security
Board & management
Six Board directors: one executive CEO/director, one non-independent non-executive chairman and four independent non-executive directors, as at28February2026. The six other management members and company secretary are not additional Board directors.
All six Board biographies print appointment11November2025. The corporate roster is separately dated31December2025. Management regional titles and the joint COO/Managing Director responsibilities are preserved.
Non-Independent Non-Executive Chairman
Board at 28 February 2026; appointed11November2025. Board Chairman, not Group CEO. As reported at 2026-02-28Chief Executive Officer; Executive Director
One current Group CEO and Executive Director, also described in management biography; not two people. Board appointed11November2025. As reported at 2026-02-28Independent Non-Executive Director; Lead Independent Director
Board at28February2026; Remuneration Committee chairman. As reported at 2026-02-28Independent Non-Executive Director
Professor Sir David Lane in the biography; same person as Sir David Lane in the31December2025 corporate roster. As reported at 2026-02-28Independent Non-Executive Director
Audit and Nominating Committees chairman; also named Tan Ng Kuang in the dated director-interest disclosure. As reported at 2026-02-28Independent Non-Executive Director
Professor Toh Han Chong; current Group Board director, distinct from other external medical appointments. As reported at 2026-02-28Chief Operating Officer; Managing Director
Managing Director (Europe and Rest of the World); executive management, not an additional Group Board seat.Chief Financial Officer
Current Group CFO.Chief Commercial Officer
Americas.Chief Commercial Officer
Ex-Americas; distinct regional commercial executive from Michael Broome.Chief Business Officer
Asia Pacific.Chief Technology Officer
Current Group technology and software executive.Company Secretary
ACIS; corporate information roster at31December2025.Roles listed in ANNUAL REPORT 2025; current appointments are not independently verified.
Holdings
Twenty registered/depository shareholders, twenty-six substantial holders and eight ownership contexts. Substantial interest columns not printed remain explicitly not printed, distinct from original zero/dash.
The repeated RGPL, AnchorVI and VerdeTaano corporate/fund/trust chains represent overlapping share blocks. Mrs Indu Rawat and Mr Mahipal Singh Rawat are expressly not Controlling Shareholders despite their beneficiary-derived deemed interests.
Share registers at18March2026, public float22.09% at24March2026. Top20 original aggregate99.09% equals the sum of individually rounded percentages; the exact aggregate share count divided by1,103,118,300 rounds to99.08%. Both original precision and the rounding distinction are retained.
Direct 683,073,042 shares; 61.92%; deemed interest not printed
At18March2026. Repeated trust/fund-chain deemed interests are overlapping shares, not additive. Three direct blocks: RGPL683,073,042; AnchorVI90,294,205; VerdeTaano76,837,111. Blank opposite interest columns are not replaced by dash or zero. As reported at 2026-03-18Direct 90,294,205 shares; 8.19%; deemed interest not printed
At18March2026. Repeated trust/fund-chain deemed interests are overlapping shares, not additive. Three direct blocks: RGPL683,073,042; AnchorVI90,294,205; VerdeTaano76,837,111. Blank opposite interest columns are not replaced by dash or zero. As reported at 2026-03-18Direct 76,837,111 shares; 6.97%; deemed interest not printed
At18March2026. Repeated trust/fund-chain deemed interests are overlapping shares, not additive. Three direct blocks: RGPL683,073,042; AnchorVI90,294,205; VerdeTaano76,837,111. Blank opposite interest columns are not replaced by dash or zero. As reported at 2026-03-1861.92%Total interest
61.92%Total interest
61.92%Total interest
61.92%Total interest
61.92%Total interest
61.92%Total interest
61.92%Total interest
61.92%Total interest
61.92%Total interest
8.19%Total interest
8.19%Total interest
8.19%Total interest
8.19%Total interest
8.19%Total interest
8.19%Total interest
8.19%Total interest
8.19%Total interest
8.19%Total interest
6.97%Total interest
6.97%Total interest
6.97%Total interest
6.97%Total interest
6.97%Total interest
1,103,118,300
Exact ordinary-share denominator. As reported at 2026-03-18Nil
Printed Nil; not a missing disclosure. As reported at 2026-03-18Nil
Printed Nil; legally defined subsidiary holdings of Company shares, not absence of operating subsidiaries. As reported at 2026-03-18Ordinary
Original share class. As reported at 2026-03-18One vote of each ordinary shares held
Original printed wording retained. As reported at 2026-03-181,346 shareholders; 1,103,118,300 shares
Original distribution aggregate. As reported at 2026-03-1899.09%Total interest
22.09%
Approximate public float as of24March2026, distinct from18March2026 registered/substantial-holder census and from shares outside top20 nominee accounts. As reported at 2026-03-24Total interests include direct and deemed holdings and may overlap across holders. These percentages should not be added together.
Registered holdings, including nominees and depositories; these do not establish ultimate beneficial ownership. As reported at 2026-03-18 · PDF p. 124
| Registered holder | Interest | Shares / units | Source |
|---|---|---|---|
| RENEW GROUP PRIVATE LIMITED | 683,073,042 shares; 61.92% | PDF p. 1242026-03-18 | |
| RAFFLES NOMINEES (PTE.) LIMITED | 107,121,611 shares; 9.71% | PDF p. 1242026-03-18 | |
| ANCHOR VI PTE. LTD. | 90,294,205 shares; 8.19% | PDF p. 1242026-03-18 | |
| HSBC (SINGAPORE) NOMINEES PTE LTD | 65,027,861 shares; 5.89% | PDF p. 1242026-03-18 | |
| BPSS NOMINEES SINGAPORE (PTE.) LTD. | 39,040,247 shares; 3.54% | PDF p. 1242026-03-18 | |
| CITIBANK NOMINEES SINGAPORE PTE LTD | 37,098,690 shares; 3.36% | PDF p. 1242026-03-18 | |
| DBS NOMINEES (PRIVATE) LIMITED | 33,527,765 shares; 3.04% | PDF p. 1242026-03-18 | |
| DBS VICKERS SECURITIES (SINGAPORE) PTE LTD | 6,683,810 shares; 0.61% | PDF p. 1242026-03-18 | |
| DBSN SERVICES PTE. LTD. | 6,580,973 shares; 0.60% | PDF p. 1242026-03-18 | |
| DB NOMINEES (SINGAPORE) PTE LTD | 5,705,100 shares; 0.52% | PDF p. 1242026-03-18 | |
| KWA CHONG SENG | 5,382,832 shares; 0.49% | PDF p. 1242026-03-18 | |
| MORGAN STANLEY ASIA (SINGAPORE) SECURITIES PTE LTD | 3,538,380 shares; 0.32% | PDF p. 1242026-03-18 | |
| MAYBANK SECURITIES PTE. LTD. | 3,510,600 shares; 0.32% | PDF p. 1242026-03-18 | |
| PHILLIP SECURITIES PTE LTD | 1,660,522 shares; 0.15% | PDF p. 1242026-03-18 | |
| OCBC SECURITIES PRIVATE LIMITED | 1,232,461 shares; 0.11% | PDF p. 1242026-03-18 | |
| IFAST FINANCIAL PTE. LTD. | 981,367 shares; 0.09% | PDF p. 1242026-03-18 | |
| CGS INTERNATIONAL SECURITIES SINGAPORE PTE. LTD. | 764,000 shares; 0.07% | PDF p. 1242026-03-18 | |
| MOOMOO FINANCIAL SINGAPORE PTE. LTD. | 744,495 shares; 0.07% | PDF p. 1242026-03-18 | |
| UOB KAY HIAN PRIVATE LIMITED | 534,700 shares; 0.05% | PDF p. 1242026-03-18 | |
| ABN AMRO CLEARING BANK N.V. | 495,100 shares; 0.04% | PDF p. 1242026-03-18 | |
Group structure
Fourteen subsidiary source rows contain eleven current wholly-owned subsidiaries and three former UltraLinQ entities disposedAugust2025. PerfusionTech moved from27.4%associate to100%subsidiaryJune2025; do not double-count it as a current associate.
One current associateFerronova, Australia26.9%versus24.6%. Two parent companies are explicitly identified above the Group and are not operating subsidiaries.
Renew Pharmaceuticals Limited and HUB Pharmaceuticals, LLC are named principal subsidiaries. New UltraGreen Data Systems entities are distinct from sold Ultralinq legal entities. Source ownership is Group effective interest, not substituted parent direct stakes.
| Company | Market | Ownership interest |
|---|---|---|
| UltraGreen DACGroup effective equity interest at31December2025 and31December2024. Held by Company.PDF p. 962025-12-31 | Ireland; current 100%; comparative 100% | |
| Ultralinq Healthcare Solutions LimitedGroup effective equity interest at31December2025 and31December2024. Held by UltraGreen DAC. Entire UltraLinQ segment disposed August2025, with loss of control; current interest dash, prior100%. Not a current subsidiary.PDF p. 962025-12-31 | United Kingdom; current –; comparative 100% | |
| Ultralinq Healthcare Solutions Inc.Group effective equity interest at31December2025 and31December2024. Held by UltraGreen DAC. Entire UltraLinQ segment disposed August2025, with loss of control; current interest dash, prior100%. Not a current subsidiary.PDF p. 962025-12-31 | United States; current –; comparative 100% | |
| Renew Pharmaceuticals LimitedGroup effective equity interest at31December2025 and31December2024. Held by UltraGreen DAC. Explicitly identified as a principal subsidiary; consolidated Group financial statements audited by KPMG LLP.PDF p. 962025-12-31 | Ireland; current 100%; comparative 100% | |
| Ultralinq Merger Sub, Inc.Group effective equity interest at31December2025 and31December2024. Held by Ultralinq Healthcare Solutions Inc.. Entire UltraLinQ segment disposed August2025, with loss of control; current interest dash, prior100%. Not a current subsidiary.PDF p. 962025-12-31 | United States; current –; comparative 100% | |
| Diagnostic Green GmbHGroup effective equity interest at31December2025 and31December2024. Held by Renew Pharmaceuticals Limited.PDF p. 962025-12-31 | Germany; current 100%; comparative 100% | |
| Diagnostic Green LimitedGroup effective equity interest at31December2025 and31December2024. Held by Renew Pharmaceuticals Limited.PDF p. 962025-12-31 | Ireland; current 100%; comparative 100% | |
| Renew Holdings, Inc.Group effective equity interest at31December2025 and31December2024. Held by Renew Pharmaceuticals Limited.PDF p. 962025-12-31 | United States; current 100%; comparative 100% | |
| Perfusion Tech ApSGroup effective equity interest at31December2025 and31December2024. Held by Renew Pharmaceuticals Limited. Former associate27.4%; remaining interest acquired June2025 and current subsidiary100%. Not counted as a second current associate merely because Note9 also lists the transition.PDF p. 962025-12-31 | Denmark; current 100%; comparative 27.4% | |
| UltraGreen Data Systems LimitedGroup effective equity interest at31December2025 and31December2024. Held by Renew Pharmaceuticals Limited. Established in2025 after UltraLinQ disposal; distinct from sold Ultralinq entities.PDF p. 962025-12-31 | United Kingdom; current 100%; comparative – | |
| Renew Hub LLCGroup effective equity interest at31December2025 and31December2024. Held by Renew Holdings, Inc..PDF p. 972025-12-31 | United States; current 100%; comparative 100% | |
| Diagnostic Green LLCGroup effective equity interest at31December2025 and31December2024. Held by Renew Holdings, Inc..PDF p. 972025-12-31 | United States; current 100%; comparative 100% | |
| UltraGreen Data Systems Inc.Group effective equity interest at31December2025 and31December2024. Held by Renew Holdings, Inc.. Established in2025 after UltraLinQ disposal; distinct from sold Ultralinq entities.PDF p. 972025-12-31 | United States; current 100%; comparative – | |
| HUB Pharmaceuticals, LLCGroup effective equity interest at31December2025 and31December2024. Held by Renew Hub LLC. Explicitly identified as a principal subsidiary; consolidated Group financial statements audited by KPMG LLP.PDF p. 972025-12-31 | United States; current 100%; comparative 100% | |
| Renew Group Private LimitedHolding company above UltraGreen.ai, not an operating subsidiary of the Group. Relationship separately described from subsidiary and associate stakes.PDF p. 73 | Singapore; immediate holding company | |
| Saul Strategic LimitedHolding company above UltraGreen.ai, not an operating subsidiary of the Group. Relationship separately described from subsidiary and associate stakes.PDF p. 73 | Singapore; ultimate holding company | |
| Ferronova Pty LtdOne current equity-accounted associate. Perfusion Tech is now a subsidiary after June2025; not a second current associate. Financial summaries disclose full investee amounts separately from Group share.PDF p. 972025-12-31 | Australia; current26.9%; comparative24.6% | |
Ownership interests and geographic information follow the annual report. Comparative years and footnote markers retain the report’s notation.
Senior executives
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Ravinder Sajwan | Chief Executive Officer and Executive Director | Management Team | PDF p. 15 |
| Declan Cassells | Chief Operating Officer and Managing Director (Europe and Rest of the World) | Group Management | PDF p. 127 |
| Eamon Lynch | Chief Financial Officer | Group Management | PDF p. 127 |
| Michael Broome | Chief Commercial Officer (Americas) | Group Management | PDF p. 127 |
| Fidelma Callanan | Chief Commercial Officer (Ex-Americas) | Group Management | PDF p. 127 |
| Quek Mei Ling | Chief Business Officer (Asia Pacific) | Group Management | PDF p. 127 |
| Theo Vouniseas | Chief Technology Officer | Group Management | PDF p. 127 |
Extracted from ANNUAL REPORT 2025 and checked against the cited pages; see the original report for full context.
Related parties, people & properties
| Item | Value | Period / scope | Source |
|---|---|---|---|
| RGPL | 144,369(1) US$'000 | Aggregate value of all interested person transactions during FY2025 (excluding <S$100,000 and Rule 920 mandate) | PDF p. 49 |
| LifeSignals Inc. | 158(2) US$'000 | Aggregate value of all interested person transactions during FY2025 (excluding <S$100,000 and Rule 920 mandate) | PDF p. 49 |
| Renew Health (UK) Limited | 296(3) US$'000 | Aggregate value of all interested person transactions during FY2025 (excluding <S$100,000 and Rule 920 mandate) | PDF p. 49 |
| Renew Health Limited | 7,143(4) US$'000 | Aggregate value of all interested person transactions during FY2025 (excluding <S$100,000 and Rule 920 mandate) | PDF p. 49 |
| ETPL Quant Limited | 1,110(5) US$'000 | Aggregate value of all interested person transactions during FY2025 (excluding <S$100,000 and Rule 920 mandate) | PDF p. 49 |
| 5-Hour International Corporation Private Limited | 220(6) US$'000 | Aggregate value of all interested person transactions during FY2025 (excluding <S$100,000 and Rule 920 mandate) | PDF p. 49 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Mr Kwa Chong Seng | 45 S$'000 | FY2025 total remuneration, Non-Executive Chairman | PDF p. 47 |
| Mr Hsieh Fu Hua | 21 S$'000 | FY2025 total remuneration, Independent Non-Executive Director and Lead Independent Director | PDF p. 47 |
| Professor Sir David Lane | 13 S$'000 | FY2025 total remuneration, Independent Non-Executive Director | PDF p. 47 |
| Mr Nicky Tan | 18 S$'000 | FY2025 total remuneration, Independent Non-Executive Director | PDF p. 47 |
| Professor Toh Han Chong | 10 S$'000 | FY2025 total remuneration, Independent Non-Executive Director | PDF p. 47 |
| Mr Ravinder Sajwan | – S$'000 | FY2025 total remuneration, Chief Executive Officer and Executive Director | PDF p. 47 |
| aggregate total remuneration paid to these key management personnel | S$3,606,415 (equivalent to US$2,741,319) | Top six key management personnel (not directors or CEO), FY2025 | PDF p. 47 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Permanent Employees | 101 count | Group, permanent employees across Singapore and Ireland | PDF p. 28 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| FY2026 Outlook: Confidence in Continued Growth | range of US$170 - US$190 million | FY2026 revenue forecast, Chairman & CEO's statement | PDF p. 19 |
| Chairman & CEO closing statement | The best is ahead. | Chairman & CEO's statement | PDF p. 19 |
Extracted from ANNUAL REPORT 2025 and checked against the cited pages; see the original report for full context.
Corporate information